Antibody Drug Conjugation at Abzena
One solution doesn’t fit all
At Abzena we understand that there is no single solution to the development of the ideal antibody drug conjugate. Every target brings its own set of challenges to the development process and optimisation of the ADC is essential in order to achieve maximum therapeutic benefit.
You can maximise your investment and streamline your ADC development program by utilising Abzena’s expertise and state-of-the-art facilities at every stage of the process. From assessing the efficacy of different conjugation and linker technologies to the synthesis of cytotoxic payloads, we can support and guide you in the development of a matrix of candidates that can be tested to find the ideal ADC for your patients.
- You can benefit from access to Abzena’s wide range of expertise and state-of-the-art facilities to streamline your ADC development program
- Take advantage of our complete target to manufacturing service offering for all ADC components
- Generate a matrix of candidates for ex-vivo assessment before committing to further development
Abzena’s services are customised to accelerate the selection of the optimal ADC candidate for your target of interest. Different conjugation technologies can be assessed for efficacy side by side, making it possible to screen and rank multiple product candidates to optimise your investment right from the beginning. Read more >>>
There are numerous antibody drug conjugation technologies available with each having their own benefits, though no single option is optimal for every payload and antibody. Abzena offers access to a variety of conjugation technologies for side by side evaluation. Read more >>>
There exists a range of payloads available for use in the development of antibody drug conjugates, each with their own toxicity profile and mechanism of action against specific tumour types. At Abzena, we can custom synthesise highly potent chemical payloads at our Bristol, USA, facility and can also develop biological payloads, including protein and DNA conjugates, at our Cambridge, UK, site. Read more >>>
Abzena’s state-of-the-art laboratories are equipped with an array of analytical instrumentation to enable full characterisation and purity determination of our products. Our capabilities range from extensive chromatographic purification equipment allowing the most challenging of separations, to our dedicated analytical suite including LCMS, MALDI-ToF and NMR spectrometers to confirm the purity, homogeneity and stability of our ADC products. Read more >>>
Abzena San Diego and Bristol sites offer large manufacturing capabilities for antibody drug conjugates at multiple scales including non-GMP and GMP manufacturing. Read more >>>